Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 8/20 | 0.32 |
| ▸ | DRD2 | P14416 | 7/20 | 0.32 |
| ▸ | DRD4 | P21917 | 4/20 | 0.32 |
| ▸ | HTR1B | P28222 | 2/20 | 0.32 |
| ▸ | HTR1D | P28221 | 2/20 | 0.32 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.32 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.32 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.32 |
| ▸ | HRH2 | P25021 | 2/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25091319 | 0.85 | TACR1 (0.35) | — | |
| SCHEMBL24775798 | 0.77 | SAT1 (0.38) | GNAI3GNAO1GNAI1 | |
| SCHEMBL12847707 | 0.72 | GNAI3 (0.37) | DRD3DRD2DRD4HTR1BHTR1D | |
| SCHEMBL2591163 | 0.72 | ALDH1A1 (0.31) | — | |
| SCHEMBL20940057 | 0.72 | EPHX1 (0.32) | — | |
| SCHEMBL25091320 | 0.71 | — | — | |
| SCHEMBL23177943 | 0.71 | KDM4E (0.36) | — | |
| SCHEMBL1678882 | 0.71 | — | — | |
| SCHEMBL5909386 | 0.71 | GNAI3 (0.45) | DRD3DRD2DRD4HTR1BHTR1D | |
| SCHEMBL21101827 | 0.70 | CYP1A2 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975088-B2 | Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors | INCYTE CORPORATION (US) | 2021-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975088-B2 | Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors | PIK3R5, PIK3CD, PIK3CA | DRD3 3934/4885DRD2 4186/4885DRD4 4605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.